Recommendations for the treatment of hepatitis B in 2017

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis B virus (HBV) infection poses significant health risks, including liver fibrosis, cirrhosis, and hepatocellular carcinoma.
• Sustained HBsAg clearance represents a key therapeutic goal, indicating functional cure and improved patient outcomes.
• Current treatment guidelines are essential for managing HBV infection effectively.

Purpose of the Study:

• To provide updated recommendations for the management of HBV infection based on the latest expert consensus.
• To outline strategies for achieving sustained HBsAg clearance in HBV-infected patients.
• To address specific patient populations and clinical scenarios, including treatment-naive patients, those with cirrhosis or hepatocellular carcinoma, and special populations.

Main Methods:

• Development of guidelines by a Polish Group of Experts for HBV in 2017.
• Review and synthesis of current scientific literature and clinical evidence.
• Formulation of evidence-based recommendations for treatment eligibility, drug selection, monitoring, and management of treatment failure.

Main Results:

• Guidelines cover assessing treatment eligibility and selecting first-line drugs for HBV infection.
• Recommendations address monitoring, treatment duration, and managing treatment failure.
• Specific advice is provided for HBV-associated cirrhosis, hepatocellular carcinoma, and special populations.

Conclusions:

• Sustained HBsAg clearance is an achievable therapeutic goal in HBV infection, leading to numerous clinical benefits.
• The 2017 Polish expert guidelines offer comprehensive recommendations for optimizing HBV management.
• These guidelines aim to improve patient outcomes, reduce disease progression, and prevent HBV transmission.